Candel Therapeutics (CADL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.19, -8.08% vs the prior close of $8.91.
- Volume 1.50M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CADL slides 8.1% to $8.19, a 3-month low, 5 down days in a row. Closed at $8.19, -8.08% vs the prior close of $8.91. Day range $8.12–$8.92, opened at $8.92.
CADL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CADL slides 8.1% to $8.19, a 3-month low, 5 down days in a row
- Closed at $8.19, -8.08% vs the prior close of $8.91. Day range $8.12–$8.92, opened at $8.92.
- Volume was 1.50M shares, 1.3x its 50-day average of 1.18M.
- Price is -27.7% vs its 50-day average ($11.33) and +0.5% vs its 200-day average ($8.15).
- 52-week range $4.35–$14.00; today's close sits at 40% of that range, 41.5% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — CADL dips 1.8% to $8.91, a 3-month low, 4 down days in a row
- Closed at $8.91, -1.76% vs the prior close of $9.07. Day range $8.79–$9.10, opened at $9.01.
- Volume was 989.30K shares, 0.8x its 50-day average of 1.18M.
- Price is -21.7% vs its 50-day average ($11.38) and +9.5% vs its 200-day average ($8.14).
- 52-week range $4.35–$14.00; today's close sits at 47% of that range, 36.4% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — CADL dips 2.2% to $9.07, a 3-month low, 3 down days in a row
- Closed at $9.07, -2.16% vs the prior close of $9.27. Day range $9.03–$9.43, opened at $9.06.
- Volume was 987.20K shares, 0.8x its 50-day average of 1.18M.
- Price is -20.5% vs its 50-day average ($11.41) and +11.7% vs its 200-day average ($8.12).
- 52-week range $4.35–$14.00; today's close sits at 49% of that range, 35.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CADL slides 5.2% to $9.27, a 3-month low
- Closed at $9.27, -5.21% vs the prior close of $9.78. Day range $9.22–$9.85, opened at $9.78.
- Volume was 1.13M shares, 1.0x its 50-day average of 1.17M.
- Price is -19.0% vs its 50-day average ($11.44) and +14.3% vs its 200-day average ($8.11).
- 52-week range $4.35–$14.00; today's close sits at 51% of that range, 33.8% below the 52-week high.
Oct 12, 2026 — CADL dips 1.6% to $9.78
- Closed at $9.78, -1.61% vs the prior close of $9.94. Day range $9.71–$10.18, opened at $10.00.
- Volume was 744.60K shares, 0.6x its 50-day average of 1.18M.
- Price is -14.6% vs its 50-day average ($11.46) and +20.9% vs its 200-day average ($8.09).
- 52-week range $4.35–$14.00; today's close sits at 56% of that range, 30.1% below the 52-week high.
Oct 9, 2026 — CADL rises 2.9% to $9.94
- Closed at $9.94, +2.90% vs the prior close of $9.66. Day range $9.59–$9.95, opened at $9.69.
- Volume was 718.10K shares, 0.6x its 50-day average of 1.18M.
- Price is -13.3% vs its 50-day average ($11.46) and +23.1% vs its 200-day average ($8.07).
- 52-week range $4.35–$14.00; today's close sits at 58% of that range, 29.0% below the 52-week high.
Oct 8, 2026 — CADL dips 1.6% to $9.66, a 1-month low, 3 down days in a row
- Closed at $9.66, -1.63% vs the prior close of $9.82. Day range $9.45–$9.76, opened at $9.70.
- Volume was 888.40K shares, 0.7x its 50-day average of 1.19M.
- Price is -15.7% vs its 50-day average ($11.46) and +20.0% vs its 200-day average ($8.05).
- 52-week range $4.35–$14.00; today's close sits at 55% of that range, 31.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — CADL dips 0.5% to $9.82, a 1-month low
- Closed at $9.82, -0.51% vs the prior close of $9.87. Day range $9.60–$9.94, opened at $9.75.
- Volume was 714.90K shares, 0.6x its 50-day average of 1.21M — lighter than usual.
- Price is -14.3% vs its 50-day average ($11.46) and +22.3% vs its 200-day average ($8.03).
- 52-week range $4.35–$14.00; today's close sits at 57% of that range, 29.9% below the 52-week high.
Oct 6, 2026 — CADL slides 3.5% to $9.87, a 1-month low
- Closed at $9.87, -3.52% vs the prior close of $10.23. Day range $9.85–$10.40, opened at $10.32.
- Volume was 976.10K shares, 0.8x its 50-day average of 1.22M.
- Price is -13.8% vs its 50-day average ($11.45) and +23.2% vs its 200-day average ($8.01).
- 52-week range $4.35–$14.00; today's close sits at 57% of that range, 29.5% below the 52-week high.
Oct 5, 2026 — CADL rises 0.5% to $10.23
- Closed at $10.23, +0.49% vs the prior close of $10.18. Day range $9.94–$10.45, opened at $10.27.
- Volume was 979.50K shares, 0.8x its 50-day average of 1.22M.
- Price is -10.7% vs its 50-day average ($11.46) and +28.1% vs its 200-day average ($7.99).
- 52-week range $4.35–$14.00; today's close sits at 61% of that range, 26.9% below the 52-week high.
Oct 2, 2026 — CADL ends flat (+0.2%) to $10.18
- Closed at $10.18, +0.20% vs the prior close of $10.16. Day range $10.03–$10.37, opened at $10.29.
- Volume was 878.40K shares, 0.7x its 50-day average of 1.22M.
- Price is -11.0% vs its 50-day average ($11.44) and +27.8% vs its 200-day average ($7.97).
- 52-week range $4.35–$14.00; today's close sits at 60% of that range, 27.3% below the 52-week high.
CADL latest news & SEC filings
Every SEC filing by or about CADL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tak Paul Peter sold 59,379 shares at $10.46 (≈$621.10K) on Sep 11, 2026
- Tak Paul Peter sold 59,379 shares at $10.46 (≈$621.10K) on Sep 11, 2026
- Tak Paul Peter sold 59,379 shares at $10.46 (≈$621.10K) on Sep 11, 2026
- Tak Paul Peter sold 59,379 shares at $10.46 (≈$621.10K) on Sep 11, 2026
- Tak Paul Peter sold 220,866 shares at $11.50 (≈$2.54M) on Sep 10, 2026
- Tak Paul Peter sold 220,866 shares at $11.50 (≈$2.54M) on Sep 10, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$38.91M (prior year -$4.80M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.52 (prior year -$0.09) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CADL
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 12, 2026, Feb 19, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.99% (largest 8.1%).
- Liquidity: about 973.81K shares (≈$7.98M) trade per day on average.
- 52-week position: $8.19 vs a range of $4.35–$14.00 (40% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 20 sales; latest: Paul Peter Tak sold 59,379 shares on Sep 11, 2026.
- Latest filings: 8-K Sep 10, 2026; 8-K Sep 9, 2026; 10-Q Aug 13, 2026.
- Share count: 76.52M shares outstanding (Aug 6, 2026), +39.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CADL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.92 | 8.92 | 8.12 | 8.19 | 1.50M |
| Oct 15, 2026 | 9.01 | 9.10 | 8.79 | 8.91 | 989.30K |
| Oct 14, 2026 | 9.06 | 9.43 | 9.03 | 9.07 | 987.20K |
| Oct 13, 2026 | 9.78 | 9.85 | 9.22 | 9.27 | 1.13M |
| Oct 12, 2026 | 10.00 | 10.18 | 9.71 | 9.78 | 744.60K |
| Oct 9, 2026 | 9.69 | 9.95 | 9.59 | 9.94 | 718.10K |
| Oct 8, 2026 | 9.70 | 9.76 | 9.45 | 9.66 | 888.40K |
| Oct 7, 2026 | 9.75 | 9.94 | 9.60 | 9.82 | 714.90K |
| Oct 6, 2026 | 10.32 | 10.40 | 9.85 | 9.87 | 976.10K |
| Oct 5, 2026 | 10.27 | 10.45 | 9.94 | 10.23 | 979.50K |
| Oct 2, 2026 | 10.29 | 10.37 | 10.03 | 10.18 | 878.40K |
| Oct 1, 2026 | 10.72 | 10.72 | 10.16 | 10.16 | 1.03M |
| Sep 30, 2026 | 11.02 | 11.24 | 10.37 | 10.44 | 1.27M |
| Sep 29, 2026 | 11.25 | 11.25 | 10.57 | 10.88 | 962.10K |
| Sep 28, 2026 | 10.98 | 11.52 | 10.76 | 11.19 | 770.80K |
| Sep 25, 2026 | 11.50 | 11.55 | 11.01 | 11.02 | 799.70K |
| Sep 24, 2026 | 11.22 | 11.59 | 10.85 | 11.55 | 880.50K |
| Sep 23, 2026 | 11.93 | 12.01 | 11.27 | 11.29 | 1.28M |
| Sep 22, 2026 | 11.28 | 11.96 | 11.15 | 11.85 | 880.30K |
| Sep 21, 2026 | 11.85 | 11.90 | 11.13 | 11.21 | 1.09M |
About Candel Therapeutics
Candel Therapeutics (CADL) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEEDHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1841387.
CADL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Edward J. Jr Benz | Director | Jun 24, 2026 |
| Renee Gaeta | Director | Jun 24, 2026 |
| Nicoletta Loggia | Director | Jul 1, 2026 |
| Paul B Manning | Director | Jul 1, 2026 |
| Christopher Martell | Director | Jun 24, 2026 |
| Gary J. Nabel | Director | Jun 24, 2026 |
| Diem Nguyen | Director | Jun 24, 2026 |
| Joseph C Papa | Director | Jul 1, 2026 |
| Maha Radhakrishnan | Director | Jun 24, 2026 |
| Paul Peter Tak | Chief Executive Officer | Sep 11, 2026 |
| Martine Zimmermann | Director | Sep 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Francesca Barone | Chief Scientific Officer | Jul 1, 2026 |
| William Garrett Nichols | Chief Medical Officer | Jan 28, 2026 |
| Charles Schoch | Chief Financial Officer | Jan 28, 2026 |
| Mark E. Sims | Chief Commercial Officer | Jul 8, 2026 |
| Paul Peter Tak | Chief Executive Officer | Sep 11, 2026 |
| Seshu Tyagarajan | Chief Technology Officer | Aug 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Tak | Sale | 59,379 | $10.46 |
| Sep 11, 2026 | Paul Peter Tak | Sale | 59,379 | $10.46 |
| Sep 11, 2026 | Paul Peter Tak | Sale | 59,379 | $10.46 |
| Sep 11, 2026 | Paul Peter Tak | Sale | 59,379 | $10.46 |
| Sep 10, 2026 | Paul Peter Tak | Sale | 220,866 | $11.50 |
| Sep 10, 2026 | Paul Peter Tak | Sale | 220,866 | $11.50 |
| Sep 10, 2026 | Paul Peter Tak | Sale | 220,866 | $11.50 |
| Sep 10, 2026 | Paul Peter Tak | Sale | 220,866 | $11.50 |
| Aug 17, 2026 | Seshu Tyagarajan | Sale | 7,000 | $12.00 |
| Aug 17, 2026 | Seshu Tyagarajan | Sale | 7,000 | $12.00 |
| Aug 17, 2026 | Seshu Tyagarajan | Sale | 7,000 | $12.00 |
| Aug 17, 2026 | Seshu Tyagarajan | Sale | 7,000 | $12.00 |
| Jun 29, 2026 | Seshu Tyagarajan | Sale | 7,000 | $10.02 |
| Jun 29, 2026 | Seshu Tyagarajan | Sale | 7,000 | $10.02 |
| Jun 29, 2026 | Seshu Tyagarajan | Sale | 7,000 | $10.02 |
CADL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-38.18M | -0.72 | $-38.31M |
| Dec 31, 2024 | — | $-55.18M | -1.74 | $-27.02M |
| Dec 31, 2023 | — | $-37.94M | -1.31 | $-34.24M |
| Dec 31, 2022 | $125.00K | $-18.79M | -0.65 | $-31.42M |
| Dec 31, 2021 | $125.00K | $-36.12M | -1.91 | $-22.22M |
Latest balance sheet: total assets $208.15M, total liabilities $82.02M, cash $201.56M (as of Jun 30, 2026).
CADL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $11.80 |
| May 14, 2026 | 8-K Item 2.02 (results) | $8.91 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $4.98 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $5.95 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $4.61 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $5.78 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $6.04 |
| May 13, 2025 | 8-K Item 2.02 (results) | $5.39 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $7.94 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $7.77 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $4.30 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CADL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.